SI-Bone (NASDAQ: SIBN) is one of 121 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare SI-Bone to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Insider and Institutional Ownership
39.5% of SI-Bone shares are held by institutional investors. Comparatively, 50.6% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.9% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares SI-Bone and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SI-Bone||$55.38 million||-$17.45 million||-23.38|
|SI-Bone Competitors||$1.48 billion||$146.48 million||42.19|
SI-Bone’s competitors have higher revenue and earnings than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations for SI-Bone and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-Bone presently has a consensus target price of $24.75, indicating a potential upside of 49.10%. As a group, “Surgical & medical instruments” companies have a potential upside of 23.88%. Given SI-Bone’s stronger consensus rating and higher possible upside, equities research analysts clearly believe SI-Bone is more favorable than its competitors.
This table compares SI-Bone and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.